Study of Aerosolized Sargramostim in Treating Patients With Melanoma Metastatic to the Lung

PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

September 30, 2000

Primary Completion Date

June 30, 2006

Study Completion Date

June 30, 2006

Conditions
Melanoma (Skin)Metastatic Cancer
Interventions
BIOLOGICAL

sargramostim

Trial Locations (18)

32224

Mayo Clinic Jacksonville, Jacksonville

55416

CCOP - Metro-Minnesota, Saint Louis Park

55805

CCOP - Duluth, Duluth

55905

Mayo Clinic Cancer Center, Rochester

56303

CentraCare Clinic, Saint Cloud

57709

Rapid City Regional Hospital, Rapid City

58122

CCOP - Merit Care Hospital, Fargo

61602

Illinois Oncology Research Association, Peoria

61801

CCOP - Carle Cancer Center, Urbana

68131

CCOP - Missouri Valley Cancer Consortium, Omaha

85259-5404

CCOP - Scottsdale Oncology Program, Scottsdale

52403-1206

CCOP - Cedar Rapids Oncology Project, Cedar Rapids

50309-1016

CCOP - Iowa Oncology Research Association, Des Moines

51101-1733

Siouxland Hematology-Oncology, Sioux City

67214-3882

CCOP - Wichita, Wichita

43623-3456

CCOP - Toledo Community Hospital Oncology Program, Toledo

17822-2001

CCOP - Geisinger Clinic and Medical Center, Danville

57105-1080

CCOP - Sioux Community Cancer Consortium, Sioux Falls

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Alliance for Clinical Trials in Oncology

OTHER

NCT00005610 - Study of Aerosolized Sargramostim in Treating Patients With Melanoma Metastatic to the Lung | Biotech Hunter | Biotech Hunter